M&A Deal Summary

Lesaffre et Compagnie SA Acquires AltarBio

On October 7, 2024, Lesaffre et Compagnie SA acquired life science company AltarBio from Ginkgo Bioworks

Acquisition Highlights
  • This is Lesaffre et Compagnie SA’s 3rd transaction in the Life Science sector.
  • This is Lesaffre et Compagnie SA’s 1st transaction in France.

M&A Deal Summary
Date 2024-10-07
Target AltarBio
Sector Life Science
Buyer(s) Lesaffre et Compagnie SA
Sellers(s) Ginkgo Bioworks
Deal Type Divestiture

Target

AltarBio

Evry-Courcouronnes, France
AltarBio is specialized in the development of microorganisms for industrial applications. Altar's technology, which was developed in collaboration with the French Alternative Energies and Atomic Energy Commission (CEA), automates Adaptive Laboratory Evolution and offers a unique capability to adapt microorganisms to the conditions required by industrial companies for their competitive utilization at commercial scale. AltarBio is based in Evry-Courcouronnes, France.

Search 199,442 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Lesaffre et Compagnie SA

Marcq-en-Baroeul, France
Category Company
Founded 1853
Sector Food
DESCRIPTION

Lesaffre et Compagnie SA is a provider in the field of yeast and fermentation products.

DEAL STATS #
Overall 7 of 7
Sector (Life Science) 3 of 3
Type (Divestiture) 1 of 1
Country (France) 1 of 1
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-09-07 Recombia Biosciences

Brisbane, California, United States

Recombia Biosciences is based on technologies for enhanced high throughput genome editing and synthetic biology and will use these technologies to discover ways in which industrial strains of yeast can be improved for manufacturing different products. Recombia Biosciences was founded in 2019 and is based in Brisbane, California.

Buy -

Seller(S) 1

SELLER

Ginkgo Bioworks

Boston, Massachusetts, United States
Category Company
Founded 2008
Sector Life Science
DESCRIPTION

Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks was established in 2008 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (France) 1 of 1
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-04-02 Modulus Therapeutics - Cell Therapy Assets

Seattle, Washington, United States

Modulus Therapeutics' Cell Therapy Assets provides chimeric antigen receptor (CAR) and switch receptor libraries.

Buy -
Mergr

Product

Company

Legal